DNAge

DNAge is a biotechnology company that develops health products targeting the aging population, focusing on solutions to address DNA damage and repair. Founded in 2004 and headquartered in Rotterdam, Netherlands, DNAge specializes in innovative health products aimed at the aging population. The company was previously acquired by Pharming Group in March 2006. DNAge has engaged in 2 investment deals, with the latest funding round being a Series A round amounting to USD 1.

940 mn, raised from investors including EQT Life Sciences and Inventages Venture Capital, bringing the total amount raised to USD 1. 940 mn. DNage Products N. V.

focuses on developing innovative health products specifically targeted at the aging population. Their flagship offering is a dietary supplement that combines two compounds recognized for their high safety profile and efficacy in addressing DNA damage and repair. This product is designed to support a lifestyle aimed at reducing degeneration associated with aging, thereby enhancing the quality of life for its users. The primary end users of DNage's products are older adults seeking to maintain their health and vitality.

The company aims to market its products across various geographical regions, although specific markets have not yet been disclosed. DNage Products N. V. generates revenue primarily through the direct sale of its dietary supplements, which are marketed to both consumers and healthcare providers.

The company may establish partnerships with retailers and wholesalers to broaden its distribution network, facilitating access to its flagship products. Revenue is derived from transactions structured around individual sales or potential subscriptions for ongoing product deliveries. Specific pricing plans and revenue structures are not publicly available, but the company’s focus on quality ingredients and health benefits suggests that its offerings are positioned within a premium market segment. Moving forward, DNAge intends to expand its portfolio by launching new dietary supplements specifically designed for the aging demographic.

The company is targeting expansion into markets across Europe and North America, with plans to implement this growth strategy by the end of 2024. The recent funding obtained through the Series A round will support product development and market entry initiatives. In March 2006, Pharming Group acquired DNAge, which may influence its strategic direction and growth potential.